[Efficacy of pneumococcal vaccination].
POLYVALENT VACCINE: Pneumococcal vaccination is based on the antigenic properties of polysides carried on the bacterial capsule which induce production of bactericidal serotype-specific antibodies. The 23 serotypes contained in the current vaccine cover 85 to 90% of all strains observed in pneumococcal infections in Europe.
Prospective and retrospective studies have demonstrated that pneumococcal vaccination can prevent 60 to 80% of invasive pneumococcal infections in immunocompetent elderly subjects and/or persons in high-risk groups with underlying disorders.


METHODS
Immunocompetent persons in the 60-65 year and older age group comprise the target population for pneumococcal vaccination. Incidence and mortality of pneumococcal infections is high in this group. Simple vaccination strategies should be implemented.
Pasteur Mérieux MSD, Lyon.
L
L
Hessel
D000328:Adult; D000368:Aged; D016470:Bacteremia / Q000276:immunology / Q000517:prevention & control; D001428:Bacterial Vaccines; D005602:France / Q000453:epidemiology; D006801:Humans; D008875:Middle Aged; D011018:Pneumonia, Pneumococcal / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control; D011446:Prospective Studies; D012189:Retrospective Studies; D018074:Vaccines, Conjugate
D001428:Bacterial Vaccines; D018074:Vaccines, Conjugate
Efficacité de la vaccination pneumococcique.